Robert Gould
Director/Board Member at FULCRUM THERAPEUTICS, INC.
Net worth: 4 M $ as of 2024-04-29
Robert Gould active positions
Companies | Position | Start | End |
---|---|---|---|
FULCRUM THERAPEUTICS, INC. | Director/Board Member | 2016-07-18 | - |
Chief Executive Officer | 2023-01-02 | 2023-06-30 | |
Director of Finance/CFO | 2023-05-10 | 2023-06-30 | |
President | 2023-01-02 | 2023-06-30 | |
TURNSTONE BIOLOGICS CORP. | Director/Board Member | 2018-12-31 | - |
Independent Dir/Board Member | 2018-12-31 | - | |
HemoShear Therapeutics, Inc.
HemoShear Therapeutics, Inc. Medical/Nursing ServicesHealth Services HemoShear Therapeutics LLC engages in the development of human-relevant systems for applications in drug research and development. It creates human relevant systems that replicate the biology of organ systems and diseases throughout drug discovery and development. The firm's technology imposes human-derived hemodynamic forces on human primary cells to recreate human biology. The company was founded by Brian R. Wamhoff and Brett R. Blackman in 2008 and is headquartered in Charlottesville, VA. | Chairman | 2022-08-24 | - |
Director/Board Member | 2015-07-08 | 2022-08-24 | |
Turnstone Biologics, Inc.
Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Director/Board Member | - | - |
Khosla Ventures LLC
Khosla Ventures LLC Investment ManagersFinance Khosla Ventures LLC (Khosla Ventures) is a venture capital firm founded in 2004 by Vinod Khosla. The firm is headquartered in Menlo Park, California. | Private Equity Investor | - | - |
Spring Arbor University | Director/Board Member | - | - |
Rubedo Life Sciences, Inc.
Rubedo Life Sciences, Inc. Packaged SoftwareTechnology Services Rubedo Life Sciences, Inc. develops intelligent drug platform to design unique, targeted and controlled therapies for age-related diseases. The company was founded by Marco Quarta, Mark Gallop and Julian Klein in 2018 and is headquartered in Silicon Valley, CA. | Director/Board Member | - | - |
Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Faeth Therapeutics, Inc. is a clinical-stage biotechnology company based in TX. The American company focuses on developing precision therapies for metabolic oncology using a machine-learning platform and a metabolic regimen involving the patient's diet. Faeth's lead program combines FTH-001 and FTH-003 with an insulin suppressing regimen to slow tumor growth by shutting down the PI3K/MTOR pathway. The company's scientific founders include Drs. Lew Cantley, Sid Mukherjee, and Karen Vousden. Anand Parikh has been the CEO since incorporation. | Director/Board Member | - | - |
Career history of Robert Gould
Former positions of Robert Gould
Companies | Position | Start | End |
---|---|---|---|
EPIZYME, INC. | Director/Board Member | 2010-02-28 | 2016-02-29 |
Chief Executive Officer | 2010-03-30 | 2015-09-09 | |
Director of Finance/CFO | 2008-02-29 | 2015-02-08 | |
President | 2008-02-29 | 2015-09-09 | |
Corporate Secretary | 2008-02-29 | 2016-02-29 | |
Treasurer | 2014-09-30 | 2015-02-08 | |
░░░ ░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - | - |
Training of Robert Gould
Spring Arbor University | Undergraduate Degree |
University of Iowa | Doctorate Degree |
Statistics
International
United States | 12 |
Canada | 2 |
Operational
Director/Board Member | 9 |
Chief Executive Officer | 2 |
Director of Finance/CFO | 2 |
Sectoral
Health Technology | 8 |
Consumer Services | 3 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
FULCRUM THERAPEUTICS, INC. | Health Technology |
TURNSTONE BIOLOGICS CORP. | Health Technology |
Private companies | 8 |
---|---|
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
HemoShear Therapeutics, Inc.
HemoShear Therapeutics, Inc. Medical/Nursing ServicesHealth Services HemoShear Therapeutics LLC engages in the development of human-relevant systems for applications in drug research and development. It creates human relevant systems that replicate the biology of organ systems and diseases throughout drug discovery and development. The firm's technology imposes human-derived hemodynamic forces on human primary cells to recreate human biology. The company was founded by Brian R. Wamhoff and Brett R. Blackman in 2008 and is headquartered in Charlottesville, VA. | Health Services |
Turnstone Biologics, Inc.
Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Health Technology |
Khosla Ventures LLC
Khosla Ventures LLC Investment ManagersFinance Khosla Ventures LLC (Khosla Ventures) is a venture capital firm founded in 2004 by Vinod Khosla. The firm is headquartered in Menlo Park, California. | Finance |
Rubedo Life Sciences, Inc.
Rubedo Life Sciences, Inc. Packaged SoftwareTechnology Services Rubedo Life Sciences, Inc. develops intelligent drug platform to design unique, targeted and controlled therapies for age-related diseases. The company was founded by Marco Quarta, Mark Gallop and Julian Klein in 2018 and is headquartered in Silicon Valley, CA. | Technology Services |
Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Faeth Therapeutics, Inc. is a clinical-stage biotechnology company based in TX. The American company focuses on developing precision therapies for metabolic oncology using a machine-learning platform and a metabolic regimen involving the patient's diet. Faeth's lead program combines FTH-001 and FTH-003 with an insulin suppressing regimen to slow tumor growth by shutting down the PI3K/MTOR pathway. The company's scientific founders include Drs. Lew Cantley, Sid Mukherjee, and Karen Vousden. Anand Parikh has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Robert Gould
- Experience